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E. H. Pieter van Dijkhuizen,1 Federica Del Chierico,2 Clara Malattia,3 Alessandra Russo,2 Denise Pires Marafon,2 
Nienke M. ter Haar,4 Silvia Magni-Manzoni,2 Sebastiaan J. Vastert,4 Bruno Dallapiccola,2 Berent Prakken,4 
Alberto Martini,3 Fabrizio De Benedetti,2 and Lorenza Putignani,2 for the Model Driven Paediatric European 
Digital Repository Consortium
Objective. To assess the composition of gut microbiota in Italian and Dutch patients with juvenile idiopathic arthri-
tis (JIA) at baseline, with inactive disease, and with persistent activity compared to healthy controls.
Methods. In a multicenter, prospective, observational cohort study, fecal samples were collected at baseline from 
78 Italian and 21 Dutch treatment- naive JIA patients with <6 months of disease duration and compared to 107 geo-
graphically matched samples from healthy children. Forty- four follow- up samples from patients with inactive disease 
and 25 follow- up samples from patients with persistent activity were analyzed. Gut microbiota composition was 
determined by 16S ribosomal RNA–based metagenomics. Alpha- and β- diversity were computed, and log ratios of 
relative abundance were compared between patients and healthy controls using random forest models and logistic 
regression.
Results. Baseline samples from Italian patients showed reduced richness compared to healthy controls (P < 
0.001). Random forest models distinguished between Italian patient baseline samples and healthy controls and sug-
gested differences between Dutch patient samples and healthy controls (areas under the curve >0.99 and 0.71, 
respectively). The operational taxonomic units (OTUs) of Erysipelotrichaceae (increased in patients), Allobaculum (de-
creased in patients), and Faecalibacterium prausnitzii (increased in patients) showed different relative abundance in 
Italian patient baseline samples compared to controls after controlling for multiple comparisons. Some OTUs differed 
between Dutch patient samples and healthy controls, but no evidence remained after controlling for multiple com-
parisons. No differences were found in paired analysis between Italian patient baseline and inactive disease samples.
Conclusion. Our findings show evidence for dysbiosis in JIA patients. Only patient/control status, age, and geo-
graphic origin appear to be drivers of the microbiota profiles, regardless of disease activity stage, inflammation, and 
markers of autoimmunity.
INTRODUCTION
The human body is host to myriad nonpathogenic microor-
ganisms, the so- called microbiota. Many factors contribute to its 
composition, among which are modes of delivery, diet, and drug 
use (1). The interaction between host and microbiota is complex 
and not yet fully elucidated. What is known is that microbiota 
play a role in host defense against pathogens and provide the 
host with nutrients and vitamins (1,2).
Recent studies have demonstrated alterations in the com-
position of gut microbiota in patients with autoimmune disor-
ders such as rheumatoid arthritis and type 1 diabetes  mellitus 
(1,3–8). These alterations of the microbial profile induce a 
dysbiotic state of the microbiota that also affects functional 
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activities of the gut (5,9). It is still unclear if there is any causal 
relationship underlying the association between dysbiosis 
and autoimmune disorders. However, various observations in 
germ- free mice are compatible with such a pathogenic role of 
gut dysbiosis (1,10,11).
Preliminary observations have suggested the presence 
of dysbiosis also in pediatric patients with juvenile idiopathic 
arthritis (JIA) (12–15). JIA is defined as any arthritis of unknown 
etiology, lasting for more than 6 weeks, with an onset before 
age 16 years (16). The study findings in JIA are interesting 
because of the hypothesized pathogenic role of the gut micro-
biota and potential therapeutic ramifications. However, these 
findings of microbiota in JIA were inconclusive, as the studies 
were small and cross- sectional, with some including patients 
with longstanding disease treated with disease- modifying anti-
rheumatic drugs (DMARDs). The differences between patients 
with active and those with inactive disease have only been 
explored within small groups. Also, the statistical analyses 
used in these studies can lead to a marked increase, up to 
68%, of the false discovery rate (FDR) (17).
Therefore, the hypothesis of whether there is dysbiosis 
in JIA patients needs to be explored further. We addressed 
the aforementioned issues in a large, multicenter longitudi-
nal study of the gut microbiota composition in a well- defined 
cohort of JIA patients at baseline and during inactive disease 
compared to healthy children.
PATIENTS AND METHODS
We conducted a multicenter, observational, prospective 
cohort study in Italy (Istituto Giannina Gaslini and Ospedale Pedi-
atrico Bambino Gesù [OPBG]) and The Netherlands (Wilhelmina 
Children’s Hospital). All consecutive patients were enrolled who 
presented between October 2013 and December 2015 with 
new- onset JIA according to the International League Against 
Rheumatism criteria (18) and with <6 months of disease duration 
since the first symptoms. Patients with systemic JIA and patients 
treated previously with DMARDs, intraarticular steroid injections, 
or systemic steroids were excluded. No patients were excluded 
for recent antibiotic exposure. Patients were included at the time 
of diagnosis and followed up every 6 months for 24 months. Col-
lected clinical data included patient demographics, JIA category, 
a full joint count, the Juvenile Arthritis Disease Activity Score 
in 71 joints (JADAS- 71) (19), physician’s global assessment of 
disease activity, parent’s or patient’s global assessment of well- 
being, the presence of active uveitis, antinuclear antibody (ANA) 
positivity, rheumatoid factor positivity, erythrocyte sedimenta-
tion rate, C- reactive protein level, and the use of nonsteroidal 
antiinflammatory drugs (NSAIDs). At the follow- up visits, data 
were collected regarding treatment and disease activity status, 
defined according to the American College of Rheumatology 
(ACR) provisional criteria for inactive disease (20).
The study was approved by the local ethics committees and 
was conducted in accordance with the Principles of Good Clinical 
Practice and the Declaration of Helsinki. Written informed consent 
was obtained from all participants.
Fecal samples. Fecal samples were collected at baseline 
and during follow- up in cases of inactive disease (defined accord-
ing to the ACR provisional criteria), persistent activity (i.e., no 
achievement of inactive disease), or disease flare (defined as the 
return of any symptom of disease activity after a period of inactive 
disease). We attempted to obtain samples as soon as inactive dis-
ease or disease flare was noted. Details of sample collection and 
analysis are specified in the Supplementary Methods, available on 
the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40827/abstract.
At the time of fecal sample collection, patient information was 
collected regarding diet; previous antibiotic, prebiotic, and probi-
otic use; and gastrointestinal infections and diagnosis of inflam-
matory bowel disorder. Also, fecal samples from healthy children, 
geographically matched with the patient baseline samples, were 
collected.
Italian healthy children were recruited at primary and sec-
ondary schools, from among the children of health workers and 
researchers at OPBG, or through collaboration with primary pedi-
atricians who enlisted children at regular check- ups. The inclu-
sion criteria for Italian healthy controls were absence of chronic 
diseases, absence of gastrointestinal infections, no antibiotic and 
preprobiotic intake in the 2 months prior to sample collection, and 
an omnivorous diet. Samples from Dutch healthy controls were 
collected at primary and secondary schools in the vicinity of the 
hospital.
Statistical analysis. To assess the overall differences 
in microbial community structure between patient groups and 
healthy controls, we calculated measures of α- diversity with 
the Chao1 and Shannon indices using the “alpha_rarefac-
tion.py” script of the QIIME software on the entire operational 
taxonomic unit (OTU) matrix (21). The Chao1 index summa-
rizes microbial diversity (richness) per sample, accounting 
for rare species that might have been missed due to under-
sampling. The Shannon index is a measure of entropy, taking 
into account species richness and evenness in the sample. 
These indices were compared between patients and con-
trols in linear regression models using age, sex, and geogra-
phy as covariates. Moreover, to estimate the dissimilarity of 
microbial communities among groups, measures of β- diver-
sity were calculated on the entire OTU matrix by unweighted 
UniFrac (22) using the scripts “beta_diversity_through_plots.
py” and “compare_categories.py” of the QIIME software (21). 
Beta- diversity measures were compared across groups using 
principal coordinates analysis (PCoA) and permutational mul-
tivariate analysis of variance (PERMANOVA). PCoA is a tech-
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nique to visualize  distances (dissimilarities) between samples 
in a lower- dimensional space. PERMANOVA compares groups 
and assesses whether the centroids or dispersion of points 
are similar between 2 groups, basing its significance test on 
random permutation of the points in the groups. Measures of 
β- diversity, as opposed to α- diversity, take into account the 
distance of OTUs along the phylogenetic tree.
After α- and β- diversity analyses, OTUs present in <20% of 
the samples were removed from the analysis (12,23–26). Since 
microbiota data are expressed as relative abundances of the 
OTUs, the sum of which equals 100% for each sample, they can-
not be analyzed using standard statistical techniques (17,27,28). 
Rather, the analysis should be based on log ratios of the individual 
parts with the geometric mean of the sample, according to the 
framework of compositional data analysis (27,28). This analysis 
was performed using the package “compositions” in R statistical 
software. Since it is impossible to take the logarithm of zero, zeros 
were imputed by means of robust imputation using the package 
“robCompositions,” as specified in the literature (29,30). Next, the 
log ratio–transformed OTU relative abundances were analyzed 
using principal components analysis (PCA), showing differences 
between Italian and Dutch patient samples, but not between 
Roman and Genovese patient samples (see Supplementary 
Figure 1, available on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40827/abstract). 
 Therefore, samples from Italian and Dutch patients were analyzed 
separately. Likewise, baseline, inactive disease, and persistent 
activity samples were analyzed separately. A random forest classi-
fication model was utilized to classify Italian patient samples taken 
at baseline and control samples, using the microbiota composi-
tion, age, and sex as covariates. To this end, the data were split 
at random into 70% for model training and 30% for model testing. 
The best model was selected in the training set, using 10- fold 
cross- validation repeated 10 times. This model was then applied 
Table 1. Clinical features of the patients and healthy controls at baseline*
Italian Dutch
Patients 
(n = 78)
Controls 
(n = 79)
Patients 
(n = 21)
Controls 
(n = 28)
Female sex 61 (78.2) 38 (48.1) 16 (76.2) 20 (71.4)
Age, median (IQR) years 3.9 (2.3–6.7) 8 (5–11) 8.5 (4.8–11.7) 8.0 (4.8–11.2)
JIA category at onset
Oligoarticular 47 (60.3) – 14 (66.7) –
Polyarticular RF positive 2 (2.6) – 0 (0) –
Polyarticular RF negative 24 (30.8) – 4 (19.0) –
Enthesitis- related 0 (0) – 2 (9.5) –
Psoriatic 3 (3.8) – 1 (4.8) –
Undifferentiated 2 (2.6) – 0 (0) –
Number of active joints, 
median (IQR)
3 (1–5) – 2 (1–4) –
PhGA, median (IQR) 6 (4–8) – 2.0 (1.5–3.0) –
PGA, median (IQR) 3.1 (1.0–5.2) – 5.7 (2.0–8.1) –
JADAS- 71, median (IQR) 13.2 (8.6–19.0) – 9.5 (6.6–13.5) –
ESR, median (IQR) mm/hour 23 (14–43) – 11 (6–31) –
ANA 51 (65.4) – 8 (38.1) –
RF 2 (2.6) – 0 (0) –
NSAIDs 62 (79.5) – 17 (81.0) –
Antibiotics 13 (16.7) 0 (0) 0 (0) 0 (0)
Prebiotics 14 (17.9) 0 (0) 8 (38.1) 9 (32.1)
Probiotics 14 (17.9) 0 (0) 0 (0) 3 (10.7)
GI infections 11 (14.1) 0 (0) 3 (14.3) 1 (3.6)
GI disorders† 6 (7.7) 0 (0) 2 (9.5) 0 (0)
* Except where indicated otherwise, values are the number (%). IQR = interquartile range; JIA = juvenile idio-
pathic arthritis; RF = rheumatoid factor; PhGA = physician’s global assessment of disease activity; PGA = par-
ent’s global assessment of disease activity; JADAS- 71 = Juvenile Arthritis Disease Activity Score in 71 joints; ESR 
= erythrocyte sedimentation rate; ANA = antinuclear antibody; NSAIDs = nonsteroidal antiinflammatory drugs. 
† Gastrointestinal (GI) disorders were constipation (n = 3), celiac disease (n = 2), milk and egg allergy (n = 1), 
abdominal bloating (n = 1), and irritable bowel syndrome and lactose intolerance (n = 1). 
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to the test set to assess its performance. The same procedure 
was used for the Dutch samples.
Differences in the log ratio–transformed relative abun-
dances of all OTUs between baseline samples and healthy 
controls, inactive disease samples and healthy controls, and 
persistent activity samples and healthy controls were assessed 
with logistic regression, using age and sex as covariates and 
patient/control status as a dependent variable. A separate 
model was fitted for each of the OTUs and each of the dis-
ease states. As mentioned above, Italian patients and healthy 
controls were analyzed separately from Dutch patients and 
healthy controls. The FDR was controlled by the Benjamini- 
Hochberg procedure (an FDR threshold of 0.05 was consid-
ered significant).
Finally, associations between the gut microbiota compo-
sitions and various clinical variables were explored using PCA, 
principal components regression, K- means clustering, and the 
Kruskal- Wallis test. Statistical analysis was carried out using R 
Statistics, version 3.3.2.
RESULTS
A total of 169 patients were initially included. Fecal sam-
ples were collected at baseline from 99 patients (78 Italian 
and 21 Dutch). Samples from the remaining patients were not 
collected due to difficulties collecting or shipping the samples. 
There were no differences between patients who provided a 
sample and patients who did not provide a sample (all vari-
ables in Table 1 were compared; data not shown). Baseline 
characteristics of the analyzed patients are shown in Table 1 
and reflect characteristics common to a population with 
recent- onset JIA. The majority of participants were female 
and most had oligoarticular JIA. Disease activity at baseline 
was moderate- to- high according to the JADAS- 71 (19,31). 
Corresponding to clinical observations, the age at disease 
onset was higher in Dutch patients when compared to Italian 
patients.
The baseline samples were matched with 107 samples 
from healthy children (Table 1). Furthermore, 44 patients con-
tributed at least 1 sample obtained during inactive disease (39 
Italian and 5 Dutch) (see Supplementary Table 1, available on 
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40827/abstract). These samples 
were collected at a median time of 1 year after diagnosis 
(range 0.3–2.0 years).
Persistent activity or flare samples were collected from 
25 patients (24 Italian and 1 Dutch) (see Supplementary Table 
2, available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40827/abstract) at a median of 0.5 years after diagnosis 
(range 0.1–1.1 years). After data filtering, a total of 998,583 
sequence reads of 16S ribosomal RNA gene amplicons were 
obtained with an average of 3,210 reads per sample and 
an average length of 487 basepairs, calculated after primer 
removal. In all samples collectively, 321 different OTUs were 
discovered. After removal of those OTUs present in <20% of 
the samples, 57 remained for analysis (see Supplementary 
Table 3, available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40827/abstract). All raw 454 sequencing reads and the 
associated metadata are available at NCBI: Bioprojects: 
PRJNA379123 and PRJNA280490 (http://www.ncbi.nlm.nih.
gov/bioproject/?term=).
Baseline samples. With age, sex, and geography as 
covariates, linear regression models showed strong evidence for 
a reduced richness, as indicated by a lower Chao1 index score, 
in baseline samples from Italian patients as compared to healthy 
controls (β = −158 [95% confidence interval (95% CI) −219, 
−97], P < 0.001). There was weak evidence that Dutch baseline 
samples had an increased richness (β = 76 [95% CI 8, 145], P = 
0.03). In both the Italian and Dutch groups, the results remained 
the same regardless of whether age was introduced as a con-
tinuous  variable or a categorical variable. Moreover, the results 
did not change when administration of antibiotics, prebiotics, or 
probiotics, or the presence of gastrointestinal disturbances were 
adjusted for as potential confounders simultaneously. Dutch 
female  controls showed lower richness than the other control 
groups (Figure 1A). There was no evidence of differences in the 
Shannon index scores. β- diversity differed between baseline sam-
ples from Italian patients and healthy controls (P = 0.001) (Fig-
ure 1B), as well as between baseline samples from Dutch patients 
and healthy controls (P = 0.013) (Figure 1C).
The random forest classification algorithm separated Italian 
patients at baseline from healthy controls almost perfectly, with 
receiver operating characteristic (ROC) curve analysis showing 
the area under the curve (AUC) as >0.99 in both training and test 
data. This was mainly due to the OTUs Allobaculum, Erysipel-
otrichaceae, Propionibacterium acnes, and Barnesiellaceae.
In the comparison of Italian patient samples at baseline and 
healthy controls, Erysipelotrichaceae, Faecalibacterium prausnit-
zii, Parabacteroides, Enterococcus, and Ruminococcaceae were 
increased, whereas Allobaculum, Gemellaceae, P acnes, and 
Turicibacter were less abundant, in patients compared to healthy 
controls (FDR- corrected P < 0.05). Table  2 shows OTUs with 
crude P values of <0.05 (see Supplementary Table 4 for full list, 
available at http://onlinelibrary.wiley.com/doi/10.1002/art.40827/
abstract). Figure 2 shows the relative abundances of the 4 OTUs 
with the strongest evidence of differences between patients and 
healthy controls.
Baseline samples from Dutch patients were separated well 
from healthy control samples by the random forest algorithm in 
the training set (AUC ROC >0.99). The most important OTUs for 
this separation were Eggerthella lenta, Rikenellaceae, Coproba-
cillus, and Mogibacteriaceae. In the test data set (n = 14), the 
AUC ROC was 0.71 (95% CI 0.41, >0.99). Various OTUs showed 
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Figure 1. Plots of ɑ- and β- diversity. A, Box plots of the Chao1 index of microbial diversity (α-diversity) in samples from Italian subjects (n = 
58 male and 99 female) and Dutch subjects (n = 13 male and 36 female). Distributions of median indices in healthy controls, baseline samples, 
inactive disease (ID), and persistent activity (PA) are shown. Linear regression models of the Chao1 index with age, sex, and geography as 
covariates show evidence of reduced richness in baseline samples, inactive disease, and persistent activity as compared to healthy controls, 
except for samples from Dutch patients at baseline. Data are shown as box plots, where lines inside the boxes represent the median. Each box 
represents the 25th to 75th percentiles. Lines outside the boxes show the highest and lowest observations still within 1.5 times the interquartile 
range removed from the upper and lower quartile, respectively. Circles indicate outliers. B and C, Principal coordinates analysis (PCoA) of 
measures of β- diversity, calculated by unweighted UniFrac in samples from Italian subjects (n = 157) (B) and Dutch subjects (n = 49) (C). 
Patients at baseline and controls (left), and baseline, inactive disease, persistent activity, and healthy controls (right) are shown. Permutational 
multivariate analysis of variance shows evidence of pairwise differences between all subgroups, except for persistent activity versus inactive 
disease samples. PC = principal component.
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a difference in relative abundance in logistic regression models, 
but no evidence of differences was maintained after FDR cor-
rection (Figure 3) (also see Supplementary Table 5, available at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40827/abstract).
Inactive disease samples. There was strong evidence of 
reduced richness, as shown by a lower Chao1 index score, in 
samples from patients with inactive disease versus healthy con-
trols using a linear regression model with age, sex, and geography 
Table 2. Differences in relative abundance between Italian patient baseline samples and healthy controls 
by separate logistic regressions
OTU*
Relative abundance 
in patients Crude P Adjusted P†
Erysipelotrichaceae Increased <0.001 <0.001
Allobaculum Decreased <0.001 <0.001
Faecalibacterium prausnitzii Increased <0.001 0.009
Gemellaceae Decreased 0.001 0.016
Propionibacterium acnes Decreased 0.002 0.016
Parabacteroides Increased 0.002 0.016
Enterococcus Decreased 0.003 0.025
Turicibacter Decreased 0.004 0.025
Ruminococcaceae Increased 0.005 0.033
Phascolarctobacterium Increased 0.012 0.07
Blautia Decreased 0.017 0.09
Barnesiellaceae Decreased 0.026 0.12
Dorea Increased 0.037 0.16
* Selected list of operational taxonomic units (OTUs) with crude P values of < 0.05. The full list can be 
accessed in Supplementary Table 4, available on the Arthritis & Rheumatology web site at http://onlineli-
brary.wiley.com/doi/10.1002/art.40827/abstract. 
† False discovery rate control using the Benjamini- Hochberg procedure. 
Figure 2. Relative abundance of the 4 operational taxonomic units with the strongest evidence of differences between Italian patient baseline 
samples (n = 78) and healthy controls (n = 79). The age of the subjects confounded the relationship between patient/control status and the 
relative abundance. Therefore, the plots were divided into patients older (top) and younger (bottom) than the median age of 6 years. The relative 
abundances are shown, and the analysis was performed on the log ratio of the relative abundances. The broken lines show the limit of detection 
at a relative abundance of 4.5 × 10−5. Relative abundances below the broken line were not observed, but were the results of imputation. Note 
the log10 transformation of the y- axis. Data are shown as box plots, where the lines inside the boxes represent the median. Each box represent 
the 25th to 75th percentiles. Lines outside the boxes show the highest and lowest observations still within 1.5 times the interquartile range 
removed from the upper and lower quartile, respectively. Circles indicate outliers.
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Figure 3. Relative abundance of the 4 operational taxonomic units with the strongest evidence of differences between Dutch patient baseline 
samples (n = 21) and healthy controls (n = 28). The age of the subjects confounded the relationship between patient/control status and the 
relative abundance. Therefore, the plots were divided into patients older (top) and younger (bottom) than the median age of 8 years. No 
evidence of differences was maintained after false discovery rate control by the Benjamini- Hochberg procedure. The relative abundances are 
shown, and the analysis was performed on the log ratio of the relative abundances. The broken lines show the limit of detection at a relative 
abundance of 4.5 × 10−5. Relative abundances below the broken line were not observed, but were the results of imputation. Note the log10 
transformation of the y- axis. Data are shown as box plots, where the lines inside the boxes represent the median. Each box represents the 25th 
and 75th percentiles. Lines outside the boxes show the highest and lowest observations still within 1.5 times the interquartile range removed 
from the upper and lower quartile, respectively. Circles indicate outliers.
Figure 4. Comparison of the differences in relative abundance in Italian patients between baseline patient samples and healthy controls 
(black), inactive disease (ID) samples and healthy controls (dark gray), and persistent activity samples and healthy controls (light gray). Values 
are the regression coefficients (odds ratio [OR]) and false coverage rate–corrected confidence intervals for the depicted operational taxonomic 
units (OTUs), obtained in a separate multivariable logistic regression analysis for each OTU, with age and sex as covariates and patient/control 
status as dependent variable. Only OTUs with an adjusted P value of <0.05 for at least 1 of the baseline, the inactive disease, or the persistent 
activity analyses are shown. Regression coefficients and confidence intervals to the left of the vertical broken line (at x = 1) denote decreased 
relative abundance in patients; values to the right of the broken line denote increased relative abundance in patients.
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as covariates (β −141 [95% CI −202, −81], P < 0.001) (Figure 1A). 
There was no evidence of differences in the Shannon index 
score. The analysis of β- diversity showed evidence of differences 
between samples from patients with inactive disease and healthy 
controls (P = 0.001), as well as between samples from patients 
with inactive disease and baseline samples (P = 0.035) (Figure 1).
Various OTUs in Italian patient inactive disease samples 
were differently abundant compared to control samples (see 
Supplementary Table 6, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.40827/abstract). Figure 4 shows the regression 
coefficients and false coverage rate–corrected CIs in comparison 
with those obtained in the analysis of baseline samples. Erysip-
elotrichaceae and F prausnitzii were increased in both baseline 
and inactive disease samples compared to healthy controls, 
whereas Allobaculum and P acnes were decreased. Enterococ-
cus, Gemellaceae, Parabacteroides, Ruminococcaceae, and 
Turicibacter showed differences at baseline, but not in inactive dis-
ease, whereas Bacteroides caccae, Barnesiellaceae, and Dorea 
showed differences in inactive disease samples, but not at base-
line. A paired analysis of selected OTUs was performed in 24 Ital-
ian patients who contributed a sample at baseline and a follow- up 
sample during inactive disease, showing no differences between 
baseline and inactive disease (see Supplementary Figure 2, avail-
able at http://onlinelibrary.wiley.com/doi/10.1002/art.40827/
abstract). However, ɑ- diversity was lower in inactive disease in this 
subset of patients (P = 0.007 by Wilcoxon’s signed rank test) (see 
Supplementary Figure 3, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.40827/abstract). No evidence for differences 
between samples from Dutch patients with inactive disease and 
healthy controls was found (see Supplementary Table 7, available 
at http://onlinelibrary.wiley.com/doi/10.1002/art.40827/abstract).
Persistent disease activity samples. Analysis of α- di-
versity showed decreased richness in samples from patients with 
persistent disease activity compared to healthy controls according 
to the Chao1 index (P = 0.004) (Figure 1). There was no evidence 
of differences according to the Shannon index. Analysis of β- di-
versity showed evidence of differences between samples from 
patients with persistent activity and healthy controls (P = 0.001). 
There was weak evidence of differences between samples from 
patients with persistent activity and baseline samples (P = 0.02), 
and very weak evidence of differences between samples from 
patients with persistent activity and samples from those with inac-
tive disease (P = 0.07) (Figure 1).
Results of the logistic regressions comparing samples from 
Italian patients with persistent activity and samples from healthy 
controls are reported in Supplementary Table 8 (available at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40827/abstract). 
Evidence of differences was found for Allobaculum and Ery-
sipelotrichaceae only. Figure 4 compares the results with those 
obtained in the baseline and inactive disease  analyses.
Clinical features. Principal components regression 
showed strong evidence that the microbiota composition dif-
fered with age (association with the first and fifth principal 
components [P < 0.001 for both]) (see Supplementary Table 
9, available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40827/abstract). A weak association was found with the 
presence of uveitis at baseline. Differently abundant OTUs 
were Blautia (P  = 0.003), Coriobacteriaceae (P = 0.009), 
Coprococcus (P = 0.03), and Lachnospiraceae (P = 0.04) (all 
P  values  unadjusted; no differences remained after FDR cor-
rection). However, only 7 patients had uveitis at baseline. No 
or weak associations were found with sex, JIA subtype, phy-
sician’s global assessment of disease activity, number of 
active joints, ANA positivity, use of NSAIDs, use of prebiotics, 
or prior gastrointestinal infections (Table 1 shows gastrointes-
tinal disorders in the cohort) (also see Supplementary Table 
9,  available  at http://onlinelibrary.wiley.com/doi/10.1002/art. 
40827/abstract).
Sensitivity analyses. The administration of antibiot-
ics or probiotics in the month prior to sample collection was 
associated with the gut microbiota composition (see Supple-
mentary Table 9). Therefore, the abovementioned analysis of 
Italian JIA patients at baseline was repeated after the exclu-
sion of subjects who had taken either antibiotics or probiotics 
(sensitivity analysis A), and showed no substantial differences. 
Likewise, a sensitivity analysis was performed after excluding 
patients with a gastrointestinal disorder (sensitivity analysis 
B), and showed no substantial differences. To explore poten-
tial confounding even further, we selected all samples within 
the same age range from among Italian patients at baseline 
and healthy controls (age range 2–15 years), simultaneously 
excluding those who took antibiotics, prebiotics or probiot-
ics, or who experienced gastrointestinal disorders (sensitivity 
analysis C), and this analysis showed no substantial differ-
ences (see Supplementary Tables 10–13, available at http:// 
onlinelibrary.wiley.com/doi/10.1002/art.40827/abstract). A fur-
ther analysis was performed calculating log ratios using simple 
multiplicative replacement of zeros in the data (29) instead of 
robust imputation, without major differences (data not shown). 
Finally, for completeness, a comparison of all OTUs (including 
those present in <20% of samples) between Italian patients at 
baseline and healthy controls was performed; the results are 
reported in Supplementary Table 3 (available at http://onlineli-
brary.wiley.com/doi/10.1002/art.40827/abstract).
DISCUSSION
This is the first study of microbiota composition in a pro-
spective inception cohort of JIA patients, taking into account 
JIA disease activity state (12,14,15). The results of our study 
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support the hypothesis that the composition of microbiota 
is different in JIA patients compared to healthy children. In 
our study, evidence was found that microbiota richness, in 
terms of rare OTUs as measured by the Chao1 index, was 
reduced in JIA patients compared to healthy controls, at base-
line, during inactive disease, and during persistent disease 
activity, especially in Italian subjects. Dutch female patients 
showed an increased richness compared to Dutch female 
healthy controls, who had a decreased richness compared to 
all other control groups (Figure  1A). Measures of β- diversity 
were different in all subgroups of patient samples compared 
to healthy controls, demonstrating the variability of microbial 
communities between groups. Differences in gut microbiota 
composition were observed between JIA patients at baseline 
and healthy children, both when classifying samples using 
the random forest algorithm (AUCs in test data >0.99 for Ital-
ian samples and 0.71 for Dutch samples, despite the Dutch 
samples not reaching traditional levels of significance in test 
data) and when analyzing the OTUs individually. Most notably, 
Erysipelotrichaceae and F prausnitzii were increased, while 
Allobaculum was decreased, in samples from Italian patients 
(Table 2 and Figure 4). Dutch patient samples were dissimilar 
to Italian patient samples, confirming the prior belief that the 
gut microbiota composition differs between these populations, 
due potentially to diet and other environmental factors. How-
ever, it could not be ruled out that the observed differences 
were due to different sample collection procedures used in the 
Italian and Dutch cohorts.
Few OTUs were differently abundant between controls 
and patients across all disease activity states. Nonetheless, 
when comparing baseline samples with paired inactive disease 
samples, no differences in relative abundance were found (Sup-
plementary Figure 2, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.40827/abstract). This finding may indicate that 
the gut microbiota profile is specific to the individuals with JIA, 
rather than disease activity status. However, it should be taken 
into account that JIA is very heterogeneous clinically, and differ-
ent diseases may be underlying the clinical symptoms. There-
fore, this conclusion is still preliminary. Finally, the results also 
indicated a strong relationship of the microbiota composition 
with age, as found previously (32,33).
In light of these results, we ask whether the microbiota 
composition is involved in the pathogenesis of JIA. Observa-
tions compatible with a pathogenic role of microbiota include 
a reduced number of Th17- and FoxP3- positive regulatory T 
cells in germ- free mice (1,2,10,11). Administration of stools 
from healthy mice to these germ- free mice led to a reconsti-
tution of Th17 numbers (34), suggesting that microbiota influ-
ence the development of the immune system. Conversely, 
inoculation of fecal samples from rheumatoid arthritis patients 
into mice led to an increase of Th17 cells and development 
of severe arthritis (3). These cell populations are of critical 
importance in immune homeostasis and play a key role in 
the pathogenesis of autoimmune diseases, including JIA 
(2,35). Additionally, in a cohort of patients with the enthesitis- 
related arthritis (ERA) subtype of JIA compared to healthy 
controls, differences in community structure were predicted 
to decrease metabolic functions. In the same cohort, a lower 
diversity of ions and underrepresentation of the tryptophan 
metabolic pathway was observed in patients (36). Trypto-
phan metabolites can lead to the production of proinflam-
matory cytokines, thus potentially linking the gut microbiota 
with inflammation (36). In another cohort of ERA patients, 
predicted functions of the gut microbiota were related to cell 
motility and chemotaxis (12). Furthermore, the risk of devel-
oping autoimmune disorders was increased following the use 
of antibiotics in early childhood. This risk was dependent on 
the number, dose, and timing of the antibiotic prescriptions 
(37,38). Our finding of a weak association with uveitis is con-
sistent with the previous finding in mouse models that acti-
vation of retina- specific T cells was dependent on gut com-
mensal microbiota (39).
Fecal microbiota transplantation has led to promising, 
though varying, results for inflammatory bowel disorders (40–43), 
and an exploratory analysis in JIA patients showed that exclu-
sive enteral feeding had an antiinflammatory effect (44). Finally, 
our finding of reduced diversity in inactive disease samples com-
pared to baseline samples (see Supplementary Figure 3, available 
at http://onlinelibrary.wiley.com/doi/10.1002/art.40827/abstract) 
supports the idea that reduced microbiota diversity is not a con-
sequence of inflammation. Nevertheless, these are preliminary 
findings, and a causal pathway has yet to be demonstrated.
The OTUs Erysipelotrichaceae, F prausnitzii, and Allobacu-
lum have been associated previously with human disease. Ery-
sipelotrichaceae appears to be highly immunogenic (45,46) and 
can potentially overgrow in the gut after treatment with broad- 
spectrum antibiotics (47). F prausnitzii was identified to have 
antiinflammatory properties, and a decreased abundance of this 
microorganism in the gut has been associated with Crohn’s dis-
ease (48) and JIA (12,14). Yet in our study it was increased in 
Italian patients at baseline. However, previous studies examined 
ERA only, whereas our cohort contained a majority of patients with 
oligoarticular and polyarticular disease. Furthermore, previous 
studies did not use compositional data analysis when comparing 
OTUs between groups. Finally, the balance among different sub-
species of F prausnitzii can result in changes in short- chain fatty 
acid production; therefore, a fine- level characterization of F praus-
nitzii strains is important to better understand their real function in 
the microbiome (49). Such a fine- level characterization was not 
available in our study. Another possibility is that F prausnitzii was 
increased as an effect, rather than a cause, of inflammation. Allo-
baculum is associated with obesity. Several studies have demon-
strated that its abundance was lower in the gut of obese mice 
(50,51) and increased in weight- reduced mice (52). Furthermore, 
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Allobaculum was positively correlated with plasma high- density 
lipoprotein concentrations in hamsters (53) and negatively corre-
lated with leptin concentration (52).
Our study has several strengths. We studied a large cohort 
of treatment- naive JIA patients compared to healthy controls. 
Patients were followed up longitudinally, allowing for the com-
parison of microbiota between various disease activity states. 
Finally, we used compositional data analysis to assess data 
expressed as proportions of a whole, such as microbiota relative 
abundances (27,28). Failure to do so can lead to an increased 
FDR, up to 68% (17).
Despite this being the largest study of gut microbiota com-
position in JIA patients, one limitation is the relatively small num-
ber of Dutch patient inactive disease and persistent disease 
activity samples, as well as the number of paired samples, which 
re- emphasizes the need for replication in future cohorts. More-
over, age and potentially sex should be matched more closely 
between patients and controls to allow for a better comparison. 
Finally, future studies should examine the mechanistic implica-
tions of gut dysbiosis in JIA.
In conclusion, our results support the hypothesis of gut 
dysbiosis in JIA patients in terms of richness and compositional 
deviation from healthy subjects. Clearly, future investigations 
should be aimed at replicating these results in other popula-
tions, elucidating the potential causal role of gut microbiota in 
the pathogenesis of JIA, and investigating the interaction among 
genetics, microbiota, and environmental factors in the develop-
ment of JIA.
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